Cancer cells tend to take up more glucose than healthy cells and metabolize it in a process called glycolysis. An enzyme called PKM2 that governs cancer cells’ preference for glucose may be a valuable anti-cancer drug target.
Cancer cells tend to take up more glucose than healthy cells and metabolize it in a process called glycolysis. An enzyme called PKM2 that governs cancer cells’ preference for glucose may be a valuable anti-cancer drug target.